Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
252 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Psoriatic Arthritis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Psoriatic Arthritis - Pipeline Review, H1 2016', provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis - The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects - The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Psoriatic Arthritis Overview 9 Therapeutics Development 10 Pipeline Products for Psoriatic Arthritis - Overview 10 Psoriatic Arthritis - Therapeutics under Development by Companies 11 Psoriatic Arthritis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Psoriatic Arthritis - Products under Development by Companies 18 Psoriatic Arthritis - Companies Involved in Therapeutics Development 22 AbbVie Inc. 22 AbGenomics International, Inc. 23 Alder Biopharmaceuticals Inc. 24 Alteogen Inc. 25 Amgen Inc. 26 AstraZeneca Plc 27 BIOCAD 28 Biocon Limited 29 Bionovis SA 30 Bristol-Myers Squibb Company 31 Celgene Corporation 32 Celltrion, Inc. 33 Coherus BioSciences, Inc. 34 Eli Lilly and Company 35 Epirus Biopharmaceuticals, Inc. 36 Forward Pharma A/S 37 Genor BioPharma Co., Ltd. 38 Innovent Biologics, Inc. 39 Johnson & Johnson 40 Kadmon Corporation, LLC 41 Kineta, Inc. 42 Mabion SA 43 Momenta Pharmaceuticals, Inc. 44 Morphotek, Inc. 45 Mycenax Biotech Inc. 46 Novo Nordisk A/S 47 Oncobiologics, Inc. 48 Panacea Biotec Limited 49 Pfizer Inc. 50 Sandoz International GmbH 51 Swedish Orphan Biovitrum AB 52 Therapeutic Proteins International, LLC 53 UCB S.A. 54 Valeant Pharmaceuticals International, Inc. 55 Vitae Pharmaceuticals, Inc. 56 Xbrane Biopharma AB 57 Psoriatic Arthritis - Therapeutics Assessment 58 Assessment by Monotherapy Products 58 Assessment by Target 59 Assessment by Mechanism of Action 62 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 abatacept - Drug Profile 69 AbGn-168H - Drug Profile 72 AbGn-168H2 - Drug Profile 73 ABT-122 - Drug Profile 74 adalimumab biosimilar - Drug Profile 76 adalimumab biosimilar - Drug Profile 77 adalimumab biosimilar - Drug Profile 79 adalimumab biosimilar - Drug Profile 80 adalimumab biosimilar - Drug Profile 81 adalimumab biosimilar - Drug Profile 82 adalimumab biosimilar - Drug Profile 83 adalimumab biosimilar - Drug Profile 84 adalimumab biosimilar - Drug Profile 85 adalimumab biosimilar - Drug Profile 86 adalimumab biosimilar - Drug Profile 87 adalimumab biosimilar - Drug Profile 89 adalimumab biosimilar - Drug Profile 90 adalimumab biosimilar - Drug Profile 91 adalimumab biosimilar - Drug Profile 92 adalimumab biosimilar - Drug Profile 93 anakinra (recombinant) - Drug Profile 94 apremilast - Drug Profile 96 bimekizumab - Drug Profile 100 brodalumab - Drug Profile 101 certolizumab pegol biosimilar - Drug Profile 103 clazakizumab - Drug Profile 104 COVA-322 - Drug Profile 106 dalazatide - Drug Profile 107 dimethyl fumarate - Drug Profile 109 DNX-114 - Drug Profile 110 etanercept - Drug Profile 111 etanercept biosimilar - Drug Profile 113 etanercept biosimilar - Drug Profile 114 etanercept biosimilar - Drug Profile 115 etanercept biosimilar - Drug Profile 116 etanercept biosimilar - Drug Profile 117 etanercept biosimilar - Drug Profile 118 etanercept biosimilar - Drug Profile 120 etanercept biosimilar - Drug Profile 121 etanercept biosimilar - Drug Profile 122 golimumab - Drug Profile 123 golimumab biosimilar - Drug Profile 127 golimumab biosimilar - Drug Profile 128 golimumab biosimilar - Drug Profile 129 guselkumab - Drug Profile 130 infliximab biosimilar - Drug Profile 133 infliximab biosimilar - Drug Profile 134 infliximab biosimilar - Drug Profile 136 infliximab biosimilar - Drug Profile 137 infliximab biosimilar - Drug Profile 139 infliximab biosimilar - Drug Profile 140 INV-17 - Drug Profile 141 itolizumab - Drug Profile 142 ixekizumab - Drug Profile 144 KANAb-071 - Drug Profile 146 KD-025 - Drug Profile 148 liraglutide (recombinant) - Drug Profile 150 risankizumab - Drug Profile 153 tofacitinib citrate - Drug Profile 155 ustekinumab biosimilar - Drug Profile 160 ustekinumab biosimilar - Drug Profile 161 VALBRO-03 - Drug Profile 162 VTP-43742 - Drug Profile 163 Psoriatic Arthritis - Recent Pipeline Updates 164 Psoriatic Arthritis - Dormant Projects 233 Psoriatic Arthritis - Discontinued Products 234 Psoriatic Arthritis - Product Development Milestones 235 Featured News & Press Releases 235 Appendix 247 Methodology 247 Coverage 247 Secondary Research 247 Primary Research 247 Expert Panel Validation 247 Contact Us 247 Disclaimer 248
List of Tables
Number of Products under Development for Psoriatic Arthritis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Development by Companies, H1 2016 (Contd..2) 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Comparative Analysis by Unknown Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Development by Companies, H1 2016 (Contd..2) 24 Products under Development by Companies, H1 2016 (Contd..3) 25 Psoriatic Arthritis - Pipeline by AbbVie Inc., H1 2016 26 Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H1 2016 27 Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H1 2016 28 Psoriatic Arthritis - Pipeline by Alteogen Inc., H1 2016 29 Psoriatic Arthritis - Pipeline by Amgen Inc., H1 2016 30 Psoriatic Arthritis - Pipeline by AstraZeneca Plc, H1 2016 31 Psoriatic Arthritis - Pipeline by BIOCAD, H1 2016 32 Psoriatic Arthritis - Pipeline by Biocon Limited, H1 2016 33 Psoriatic Arthritis - Pipeline by Bionovis SA, H1 2016 34 Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2016 35 Psoriatic Arthritis - Pipeline by Celgene Corporation, H1 2016 36 Psoriatic Arthritis - Pipeline by Celltrion, Inc., H1 2016 37 Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H1 2016 38 Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H1 2016 39 Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 40 Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H1 2016 41 Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H1 2016 42 Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H1 2016 43 Psoriatic Arthritis - Pipeline by Johnson & Johnson, H1 2016 44 Psoriatic Arthritis - Pipeline by Kadmon Corporation, LLC, H1 2016 45 Psoriatic Arthritis - Pipeline by Kineta, Inc., H1 2016 46 Psoriatic Arthritis - Pipeline by Mabion SA, H1 2016 47 Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 48 Psoriatic Arthritis - Pipeline by Morphotek, Inc., H1 2016 49 Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H1 2016 50 Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H1 2016 51 Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H1 2016 52 Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H1 2016 53 Psoriatic Arthritis - Pipeline by Pfizer Inc., H1 2016 54 Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H1 2016 55 Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2016 56 Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H1 2016 57 Psoriatic Arthritis - Pipeline by UCB S.A., H1 2016 58 Psoriatic Arthritis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 59 Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 60 Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H1 2016 61 Assessment by Monotherapy Products, H1 2016 62 Number of Products by Stage and Target, H1 2016 64 Number of Products by Stage and Mechanism of Action, H1 2016 67 Number of Products by Stage and Route of Administration, H1 2016 70 Number of Products by Stage and Molecule Type, H1 2016 72 Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H1 2016 168 Psoriatic Arthritis - Dormant Projects, H1 2016 237 Psoriatic Arthritis - Discontinued Products, H1 2016 238
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
